SRNE

Sorrento Therapeutics Inc. (SRNE) | Rumor.io

Sorrento Therapeutics

SRNE

Attention (50-day avg)0%

Attention rank (50-day avg)#3,372

Bullish sentiment (50-day avg)67%

Price to earnings ratio-0

Market capitalization441K

Earnings per share-0.14

Dividend yield (TTM)—

Revenue (annual)62.8M

Net income (annual)-577.8M

Social

What share of all stock conversation is about SRNE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Oct 10

Sorrento Therapeutics, Inc. (SRNE) emerged from Chapter 11 bankruptcy proceedings in April 2024, but is now operating as a liquidating trust, focusing on winding down operations and distributing assets to creditors.
The company's shareholders have likely been wiped out, and the bankruptcy filing was due to mounting debt and legal battles.
Some investors believe SRNE's price will increase due to a potential buyout and short covering, with some speculating a price of $10 or higher.

Generated by AI

Sentiment

Of the messages about SRNE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -80	69.54% +4.6
Bearish	—	—	100% +80	30.46% -4.6

Bullish· Apr 15

SRNE has a strong pipeline with potential for significant growth.
The company's expert team has a deep understanding of trading and can navigate the challenges of a low-priced stock.
SRNE is likely to see a significant price increase, potentially reaching $5 or more per share, based on current trends and expert analysis.

Bearish· Jan 19

The company's accounting system has been plagued by problems, with the CFO being fired and the company warning in filings that the system was not accurate.
The company's market capitalization has been severely reduced, with an 18% loss in value since the previous mention.
The company's actions have been likened to a scam, with accusations of market manipulation and naked short selling, and some individuals calling for the perpetrators to be held accountable.

Generated by AI

Topics

Of the messages about SRNE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	75%	65.91%
Controversies	—	0%	25%	31.82%
Analysts	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	2.27%

Earnings· Mar 26

Sorrento Therapeutics, Inc. ($SRNE) is set to release earnings tomorrow at pm.

Analysts· Jan 29

Analyst B. Riley Securities initiated coverage of Sorrento Therapeutics with a Buy rating and $26 price target, citing the company's well-positioned therapeutic antibodies for various diseases.
The average price target for Sorrento Therapeutics is $28.00, representing a 121.17% increase from the last price of $12.66, with a high forecast of $35.00 and a low forecast of $21.00.
Four analysts have initiated Buy ratings on Sorrento Therapeutics, with an average price target of $28.67, and the company's Relative Strength (RS) Rating has been upgraded from 90 to 93.

Announcements· Feb 22

Sorrento Therapeutics, Inc. (SRNE) receives court approval for $75 million financing in Chapter 11 case, providing immediate liquidity for the company.
The financing will allow SRNE to continue operating its business as usual during its Chapter 11 case, filed on February 13, 2023.
SRNE's restricted dividend for SCLX, a subsidiary, may create chaos for short sellers, potentially leading to a takeover or buyout offer for the company.

Controversies· Mar 20

A judge has ruled against Nant Pharma, removing them from the committee of creditors, which may aid Sorrento Therapeutics in collecting a $125 million award against Nant.
The judge's decision appears to be a significant victory for Sorrento, with some commentators expressing surprise and approval of the ruling.
Sorrento Therapeutics is involved in a lawsuit with Nant Pharma over a $125 million award, with the case potentially going to trial in July if a settlement is not reached.

Technical Analysis· Feb 21

Key support levels for $SRNE include $0.39, with a break above $0.4350 expected and a potential target of $0.50+.
The stock has held up well on its bottom consolidation, nearing a pivot into power hour, with a demand zone identified at $0.38 to $0.43 and a momentum indicator at $0.44.
A positive convergence of the 9ma and 50 MA on the 15min chart is expected to drive a pop in the stock, potentially breaking current day's high at $0.46.

Generated by AI

Community

Of the messages about SRNE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	27.78%	77.22%
Newcomers	—	100%	72.22%	22.78%

Regulars· Feb 22

Sorrento Therapeutics, Inc. (SRNE) has received court approval for a $75 million financing in its Chapter 11 case, which could be a crucial step in the company's restructuring.
The stock's price has been volatile, with some users reporting a 77% profit on a bankruptcy arbitrage trade and others experiencing significant losses.
The company's bankruptcy filing has been a major topic of discussion, with some users expressing optimism about the potential for a turnaround and others cautioning that the stock's price is still subject to significant volatility.

Newcomers· Feb 22

$SRNE stock has potential to go up after hitting a 52-week low, with some good news that could propel it towards $1.
The company has received court approval for $75M financing in Chapter 11 case, which could lead to a gap up after-hours.
A #shortsqueeze could 2-3x the asset overnight due to Sorrento's ownership of 135M shares of Scilex, a $1 BILLION stake that could be triggered when Scilex squeezes.

Generated by AI

Also Discussed

Investors talking about SRNE also mention

#	Name	Attention
1	Scilex Holding Co.SCLX	0%new
2	Co-Diagnostics Inc.CODX	0%+0
3	VXRT - Vaxart, Inc.	——
4	Inovio Pharmaceuticals Inc.INO	0%+0
5	Celularity Inc. Class A Common StockCELU	0%0
6	VBIV - VBI Vaccines Inc.	——
7	iBio, Inc.IBIO	0%0
8	Novavax Inc.NVAX	0.06%+0.01
9	Eastman Kodak CompanyKODK	0%0
10	Remark Holdings Inc.MARK	0%0

Sorrento Therapeutics Inc.

Healthcare
Biotechnology

Sorrento Therapeutics Inc. is a clinical and commercial stage biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs. It focuses on cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases by leveraging proprietary technologies such as the G-MAB antibody library and targeted delivery modalities like CAR-T and DAR-T cell therapies. The company also develops pain management solutions, including resiniferatoxin and SEMDEXA, and has been involved in COVID-19 therapeutic and vaccine development. Sorrento Therapeutics operates across multiple sectors in the healthcare industry, contributing to advancements in biotechnology and pharmaceuticals.

Website

Location

4955 Directors Place

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about SRNE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Oct 10

Sorrento Therapeutics, Inc. (SRNE) emerged from Chapter 11 bankruptcy proceedings in April 2024, but is now operating as a liquidating trust, focusing on winding down operations and distributing assets to creditors.
The company's shareholders have likely been wiped out, and the bankruptcy filing was due to mounting debt and legal battles.
Some investors believe SRNE's price will increase due to a potential buyout and short covering, with some speculating a price of $10 or higher.

Generated by AI

Sentiment

Of the messages about SRNE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -80	69.54% +4.6
Bearish	—	—	100% +80	30.46% -4.6

Bullish· Apr 15

SRNE has a strong pipeline with potential for significant growth.
The company's expert team has a deep understanding of trading and can navigate the challenges of a low-priced stock.
SRNE is likely to see a significant price increase, potentially reaching $5 or more per share, based on current trends and expert analysis.

Bearish· Jan 19

The company's accounting system has been plagued by problems, with the CFO being fired and the company warning in filings that the system was not accurate.
The company's market capitalization has been severely reduced, with an 18% loss in value since the previous mention.
The company's actions have been likened to a scam, with accusations of market manipulation and naked short selling, and some individuals calling for the perpetrators to be held accountable.

Generated by AI

Topics

Of the messages about SRNE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	75%	65.91%
Controversies	—	0%	25%	31.82%
Analysts	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	2.27%

Earnings· Mar 26

Sorrento Therapeutics, Inc. ($SRNE) is set to release earnings tomorrow at pm.

Analysts· Jan 29

Analyst B. Riley Securities initiated coverage of Sorrento Therapeutics with a Buy rating and $26 price target, citing the company's well-positioned therapeutic antibodies for various diseases.
The average price target for Sorrento Therapeutics is $28.00, representing a 121.17% increase from the last price of $12.66, with a high forecast of $35.00 and a low forecast of $21.00.
Four analysts have initiated Buy ratings on Sorrento Therapeutics, with an average price target of $28.67, and the company's Relative Strength (RS) Rating has been upgraded from 90 to 93.

Announcements· Feb 22

Sorrento Therapeutics, Inc. (SRNE) receives court approval for $75 million financing in Chapter 11 case, providing immediate liquidity for the company.
The financing will allow SRNE to continue operating its business as usual during its Chapter 11 case, filed on February 13, 2023.
SRNE's restricted dividend for SCLX, a subsidiary, may create chaos for short sellers, potentially leading to a takeover or buyout offer for the company.

Controversies· Mar 20

A judge has ruled against Nant Pharma, removing them from the committee of creditors, which may aid Sorrento Therapeutics in collecting a $125 million award against Nant.
The judge's decision appears to be a significant victory for Sorrento, with some commentators expressing surprise and approval of the ruling.
Sorrento Therapeutics is involved in a lawsuit with Nant Pharma over a $125 million award, with the case potentially going to trial in July if a settlement is not reached.

Technical Analysis· Feb 21

Key support levels for $SRNE include $0.39, with a break above $0.4350 expected and a potential target of $0.50+.
The stock has held up well on its bottom consolidation, nearing a pivot into power hour, with a demand zone identified at $0.38 to $0.43 and a momentum indicator at $0.44.
A positive convergence of the 9ma and 50 MA on the 15min chart is expected to drive a pop in the stock, potentially breaking current day's high at $0.46.

Generated by AI

Community

Of the messages about SRNE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	27.78%	77.22%
Newcomers	—	100%	72.22%	22.78%

Regulars· Feb 22

Sorrento Therapeutics, Inc. (SRNE) has received court approval for a $75 million financing in its Chapter 11 case, which could be a crucial step in the company's restructuring.
The stock's price has been volatile, with some users reporting a 77% profit on a bankruptcy arbitrage trade and others experiencing significant losses.
The company's bankruptcy filing has been a major topic of discussion, with some users expressing optimism about the potential for a turnaround and others cautioning that the stock's price is still subject to significant volatility.

Newcomers· Feb 22

$SRNE stock has potential to go up after hitting a 52-week low, with some good news that could propel it towards $1.
The company has received court approval for $75M financing in Chapter 11 case, which could lead to a gap up after-hours.
A #shortsqueeze could 2-3x the asset overnight due to Sorrento's ownership of 135M shares of Scilex, a $1 BILLION stake that could be triggered when Scilex squeezes.

Generated by AI

Sorrento Therapeutics

Social

Oct 10

Sentiment

Bullish· Apr 15

Bearish· Jan 19

Topics

Earnings· Mar 26

Analysts· Jan 29

Announcements· Feb 22

Controversies· Mar 20

Technical Analysis· Feb 21

Community

Regulars· Feb 22

Newcomers· Feb 22

Also Discussed

Sorrento Therapeutics Inc.

Company Information

Location

Also Discussed

Social

Oct 10

Sentiment

Bullish· Apr 15

Bearish· Jan 19

Topics

Earnings· Mar 26

Analysts· Jan 29

Announcements· Feb 22

Controversies· Mar 20

Technical Analysis· Feb 21

Community

Regulars· Feb 22

Newcomers· Feb 22